XML 55 R31.htm IDEA: XBRL DOCUMENT
v3.10.0.1

Collaborative Arrangements (Tables) | 12 Months Ended
--- | ---
Dec. 31, 2018
Collaborative Arrangements [Abstract] |
Schedule of Collaborative Arrangements | Summarized information related to this collaboration is as follows:
Years Ended December 31 | 2018 |  | 2017 |  | 2016
Net product sales recorded by Merck | $ | 190 |  |  | $ | 149 |  |  | $ | 88 |
Merck’s profit share from sales in Bayer’s marketing territories | 139 |  |  | 151 |  |  | 81 |
Total sales | 329 |  |  | 300 |  |  | 169 |
Cost of sales (1) | 216 |  |  | 99 |  |  | 133 |
Selling, general and administrative | 35 |  |  | 27 |  |  | 26 |
Research and development | 127 |  |  | 101 |  |  | 82 |
December 31 |  |  | 2018 |  | 2017 |
Receivables from Bayer included in Other current assets |  |  | $ | 32 |  |  | $ | 33 |
Payables to Bayer included in Accrued and other current liabilities (2) |  |  | — |  |  | 350 |
Payables to Bayer included in Other Noncurrent Liabilities (2) |  |  | 375 |  |  | — |
(1) Includes amortization of intangible assets. (2) Includes accrued milestone payments. Summarized information related to this collaboration is as follows:
Year Ended December 31 | 2018
Alliance revenue | $ | 149 |
Cost of sales (1) | 39 |
Selling, general and administrative | 13 |
Research and development (2) | 1,489 |
December 31 | 2018
Receivables from Eisai included in Other current assets | $ | 71 |
Payables to Eisai included in Accrued and other current liabilities (3) | 375 |
Payables to Eisai included in Other Noncurrent Liabilities (3) | 543 |
(1) Represents amortization of capitalized milestone payments. (2) Includes $1.4 billion related to the upfront payment and future option payments. (3) Includes accrued milestone and option payments. nt testing. Summarized information related to this collaboration is as follows:
Years Ended December 31 | 2018 |  | 2017
Alliance revenue | $ | 187 |  |  | $ | 20 |
Cost of sales (1) | 93 |  |  | 4 |
Selling, general and administrative | 48 |  |  | 1 |
Research and development (2) | 152 |  |  | 2,419 |
December 31 | 2018 |  | 2017
Receivables from AstraZeneca included in Other current assets | $ | 52 |  |  | $ | 12 |
Payables to AstraZeneca included in Accrued and other current liabilities (3) | 405 |  |  | 543 |
Payables to AstraZeneca included Other Noncurrent Liabilities (3) | 250 |  |  | 100 |
(1) Represents amortization of capitalized milestone payments. (2) Amount for 2017 includes $2.35 billion related to the upfront payment and future license option payments. (3) Includes accrued milestone and license option payments.

X
- Definition Collaborative Arrangements [Abstract] + References No definition available. + Details
Name: | mrk_CollaborativeArrangementsAbstract
Namespace Prefix: | mrk_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Publisher FASB -Name Accounting Standards Codification -Topic 808 -SubTopic 10 -Section 50 -Paragraph 1 -URI http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434 + Details
Name: | us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration